If you are not able to attend LIVE and want to ask a question then please leave it in the comments below and will be discussed during the event

Let me know in the comments any feedback Thank you

I will be discussing my take on the recently announced failure of Pelacarsen to lower cardiac events in patients with elevated Lp(a) If you are unable to attend LIVE and want to ask a question, then please leave the question in the comments of this posts and I will answer it We will see how a hybrid of asynchronous questions with Live questions work to increase the volume of questions and educational opportunities for this group's members

The Lp(a) story continues to be one of the most exciting developments in preventive cardiology, and this week brought fresh pipeline context: • Muvalaplin (Eli Lilly) — oral Lp(a)-lowering agent, Phase 2 data complete, Phase 3 underway at UC Health and other centers • Lepodisiran (诺华/Novartis) — siRNA agent, single injection showing reductions of ~90%+ in Phase 1/2; ACCLAIM-Lp(a) trial active • Olpasiran (安进/Amgen) — siRNA, similar efficacy profile • Pelacarsen (Ionis/AstraZeneca) — ASO agent, earliest in development The HORIZON trial — first dedicated cardiovascular outcomes trial for an Lp(a)-lowering agent — is expected to report before end of 2026. This is the data that will tell us whether lowering Lp(a) actually reduces events the way LDL lowering does. If HORIZON is positive, Lp(a) screening moves from "interesting but untreatable" to "actionable cardiovascular risk factor" — a massive shift in preventive cardiology practice. Source: UCHealth Today, August 4 · [Family Heart Foundation / ACC/AHA 2026 Guideline]

August marks a pivotal moment in preventive cardiology — a new guideline settling into practice, a major anti-inflammatory trial disappointment, a breakthrough therapy for a neglected condition, and one of cardiology's largest congresses about to unfold. Here's everything worth knowing. ─── 1. The 2026 Dyslipidemia Guideline Is Here — And It Changes Everything The ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia dropped in March 2026, and August is when clinicians are actually starting to apply it. The core shift: treat earlier, target lower. The guideline introduces the "CPR" model for every patient encounter: • *C*alculate — Use the new PREVENT score to get 10-year and 30-year risk estimates • *P*ersonalize — Factor in risk enhancers the calculator doesn't capture: family history, Lp(a), hsCRP, reproductive history, chronic inflammatory conditions • *R*eclassify — Use the CAC score to reclassify and potentially escalate or de-escalate therapy The LDL-C targets are concrete now — not just percent reductions: | Risk Level | LDL-C Goal | Non-HDL-C Goal | | --------------------------------- | ---------- | -------------- | | High (≥10% 10-yr PREVENT) | <70 mg/dL | <100 mg/dL | | Borderline / Intermediate (3–10%) | <100 mg/dL | <130 mg/dL | Lp(a) gets its first-ever universal screening recommendation from ACC/AHA — measure it at least once in every adult. This is a major upgrade from prior guidance. Values >125 nmol/L carry ~1.4× ASCVD risk; >250 nmol/L carry ≥2× risk. One blood test. Lifetime implications forcascade screening. ─── 2. ZEUS Trial: The Anti-Inflammatory Hypothesis Takes a Hit Novo Nordisk's ziltivekimab — a monoclonal antibody targeting interleukin-6 (IL-6), the inflammation cytokine thought to be a central driver of residual cardiovascular risk — failed to reduce major adverse cardiovascular events in the phase 3 ZEUS trial. Despite ziltivekimab demonstrating robust biological activity — significant drops in IL-6 and CRP — the primary MACE endpoint (MI, stroke, CV death) was not met. HR 0.99. Neutral.